OA11376A - Thienopyrimidine and thienopyridine derivatives useful as anticancer agents. - Google Patents
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents. Download PDFInfo
- Publication number
- OA11376A OA11376A OA1200000133A OA1200000133A OA11376A OA 11376 A OA11376 A OA 11376A OA 1200000133 A OA1200000133 A OA 1200000133A OA 1200000133 A OA1200000133 A OA 1200000133A OA 11376 A OA11376 A OA 11376A
- Authority
- OA
- OAPI
- Prior art keywords
- thieno
- phenyl
- indol
- pyrimidin
- amine
- Prior art date
Links
- 0 *c1cc(nccc2Cl)c2[s]1 Chemical compound *c1cc(nccc2Cl)c2[s]1 0.000 description 3
- TWEQNZZOOFKOER-UHFFFAOYSA-N COC(c([s]cc1)c1N)=O Chemical compound COC(c([s]cc1)c1N)=O TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 1
- GYQUXKQLCNFKQT-UHFFFAOYSA-N Clc1c2[s]ccc2ncc1 Chemical compound Clc1c2[s]ccc2ncc1 GYQUXKQLCNFKQT-UHFFFAOYSA-N 0.000 description 1
- DKGYESBFCGKOJC-UHFFFAOYSA-N Nc1c[s]cc1 Chemical compound Nc1c[s]cc1 DKGYESBFCGKOJC-UHFFFAOYSA-N 0.000 description 1
- AACVULYSNJAKEQ-UHFFFAOYSA-N O=C1c([s]cc2)c2NC=C1 Chemical compound O=C1c([s]cc2)c2NC=C1 AACVULYSNJAKEQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (30)
- -67- 011376 5 CLAIMSor a pharmaceuticalty acceptable sait or hydrate thereof, wherein:wherein X1 is N or CH; 10 R1 is H, Ci-C6 alkyl or -C(O)(C,-C6 alkyl); R2 is Ce-Cw aryl or 5-13 membered heterocyclic, wherein said R2 groups are optionallysubstituted by 1 to 5 R5 substituents, each R3 is independently selected from H, -C(O)OR9, and Ci-C6 alkyl wherein said alkyl isoptionally substituted by 1 to 3 R5 groups; 15 R4 is R3, -OR9, or -NR9R10; each R5 is independently selected from halo, cyano, nitro, trifluoromethoxy,trifluoromethyl, azido, -C(O)R8. -C(O)OR8, -OC(O)R8, -OC(O)OR8, -NR6C(O)R7, -C(O)NR6R7,-NR®R7. -OR9, -SO2NR6R7, C,-C6 alkyl, -(CH2)iO(CH2)qNR6R7, -(CH2),O(CH2)„OR9. -(CH2),OR9,-S(O)j(Ci-C6 alkyl), -(CH2),(C6-C10 aryl), -(CH2),(5-10 membered heterocyclic), -C(O)(CH2),(C6- 20 C10 aryl), -(CH2),O(CH2)j(C6-C50 aryl), -(CH2),O(CH2)q(5-10 membered heterocyclic). -C(O)(CH2)t(5-10 membered heterocyclic), -(CH2)jNR7(CH2)qNR6R7, -<CH2)iNR7CH2C(O)NR6R7,-(CH2)jNR7(CH2)qNR9C(O)R8, -(CH2)iNR7(CH2),O(CH2)qOR9. -(CH2)jNR7(CH2)„S(O)1(C,-C6 alkyl).-(CH2)jNR7(CH2),R6. -S02(CH2)t(C6-C1o aryl), and -SO2(CH2),(5-10 membered heterocyclic), , wherein j is an integer ranging from 0 to 2, t is an integer ranging from 0 to 6, q is an integer 25 ranging from 2 to 6, the -(CH2)q- and -(CH2)t- moieties of the foregoing Rs groups optionallyinclude a carbon-carbon double or triple bond where t is an integer between 2 and 6, and thealkyl, aryl and heterocyclic moieties of the foregoing R5 groups are optionally substituted by 1 to3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R8,-C(O)OR8, -OC(O)R8, -OC(O)OR8, -NReC(O)R7, -C(O)NR6R7, -<CH2),NR6R7, CrC6 alkyl, 30 -(CH2),(C6-C,o aryl), -(CH2),(5-10 membered heterocyclic), -(CH2),O(CH2)„OR9, and -(CH2),OR9. wherein t is an integer ranging from 0 to 6 and q is an integer ranging from 2 to 6; each R6 and R7 is independently selected from H, C,-C6 alkyl, -(CH2),(C6-Ci0 aryl),-(CH2),(5-10 membered heterocyclic). -(CH2),O(CH2)qOR9. and -{CH2),OR9, wherein t is aninteger ranging from 0 to 6 and q is an integer ranging from 2 to 6, and the alkyl, aryl and 35 heterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted by 1 to 3substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R8, -68- 011376 10 15 20 25 30 -C(O)0R8. -CO(O)R8, -0C(O)OR8, -NR9C(O)Rw, -C(O)NR9Rw, -NR9Rw, c,-c6 alkyl,-(CH2),(C6-C,o aryl), -(CH2),(5-10 membered heterocyclic), -(CH2),O(CH2)qOR9, and -(CH2),OR9.wherein t is an integer ranging from 0 to 6 and q is an integer ranging from 2 to 6, with theproviso that where R6 and R7 are both attached to the same nitrogen, then R6 and R7 are notboth bonded to the nitrogen directly through an oxygen; each R8 is independently selected from H, C,-Cw alkyl, -(CH2),(C6-C,o aryl), and-(CH2),(5-10 membered heterocyclic), wherein t is an integer ranging from 0 to 6; each R9 and R10 is independently selected from H and CrC6 alkyl; R" is H, CrC6 alkyl, -C(O)NR®R9, -C(O)(C6-C,0 aryl), -{CHjMCe-Cw aryl), or -<CH2),(5-10membered heterocyclic), wherein t is an integer ranging from 0 to 6, wherein said R11 groups,otherthan H, are optionally substituted by 1 to 5 R5 groups; and, R12 is H, C,-C6 alkyl, -C(O)(Ci-Cs alkoxy), -8(0)/0,-06 alkyl), -SO2(CH2),(C6-CW aryl),-(CH2),(Ce-C,o aryl), -(CH2),(5-10 membered heterocyclic), -(CH2),O(CH2)qOR9, or -(CH2),OR9,wherein j is an integer ranging from 0 to 2, t is an integer ranging from 0 to 6 and q is an integerranging from 2 to 6.
- 2- Diethylaminomethyl-4-(6-phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenol;5-Methyl-1-[4-(6-phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenyl]-1,2-dihydro-pyrazol-3- one; [4-(4,5-Dichloro-imidazol-1-yl)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 10 (6-Phenyl-thieno[3,2-dlpyrimidin-4-yl)-[4-(3-trifluoromethyl-pyrazol-1 -yl)-phenyl]-amine; (4-(4-Methyl-pipera2in-1-yl)-phenyl]-(6-phenyl-thieno{3I2-dÎpyrimidin-4-yl)-amine;[4-<4-Methyl-piperidin-1-yl)-phenyl]-(6-phenyl-thienof3,2-d]pyrimidin-4-yl)-amine; l-{4-(6-Phenyl-thienol3,2-d]pyrimidin-4-ylamino)-phenyl]-1H-tetrazole-5-thiol; 3- (6-PhenyHhieno[3,2-d]pyrimidin-4-ylamino)-benzenesulfonamide; 15 (2-Methyl-benzothiazol-6-yl)-(6-Pheriyl-thieno(3,2-d]pyrimidin-4-yl>-amine; [4-(Morpholine-4-sulfonyl)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; (3,5-Dimethyl-4-(thiophen-3-yimethoxy)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)- amine; [4,5-Dimethoxy-2-(1H-tetrazol-5-yl)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)- 20 amine; 5- [4-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenyl]-oxazolidine-2,4-dione;1-Ethyl-5-<6-phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-1,3-dihydro-indol-2-one; 6- (6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-3H-benzooxazol-2-one;Dibenzothiophen-4-yl-(6-phenyt-thieno[3,2-d]pyrimidin-4-yl)-amine; 25 N-(6-Pheny1-thieno[3,2-d]pyrimidin-4-yl)-N'-p-tolyt-benzene-1,2-diamine; (2-Furan-2-yl-1-methyl-1H-benzoimidazol-5-yl)-{6-phenyl-thieno[3,2-d]pyrimidin-4-yl)- amine; 5-(6-Phenyl-thieno(3,2-d]pyrimidin-4-ylamino)-benzo[b]thiophene-2-carbonitrile; (6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-{2-pyridin-4-yl-1H-benzoimidazol-5-yl)-amine; 30 [4-( 1 -Methyl-1 H-imidazol-2-ylsulfanyl)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)- amine; (6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-[4-(pyridin-2-yloxy)-phenyl]-amine; [4-(5-Methyl-tetrazol-1-yl)-phenyl]-{6-phenyl-thieno[3,2-d]pyrimidin-4-yf)-amine; 1-[3-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamÎno)-phenyl]-1H-tetrazole-5-thiol; 35 4-[4-(6-Phenyl-thieno[3,2-dJpyrimidin-4-ylamino)-phenylamino]-phenol; [3-{3-Methyi-4,5-dihydro-pyrazol-1-yl)-phenyI]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)- amine; [6-{4-Fluoro-phenyl)-thieno[3,2-d]pyriniidin-4-yl]-(1H-indol-5-yl)-amine; Benzo[1,2,3]thiadiazol-6-yl-(6-phenyl-thieno[3,2-<i]pyrimidin~4-yl)-amine; 40 and the pharmaceutically acceptable salts and hydrates of the foregoing compounds.2-Amino-3-(3-{4-(4-( 1 H-indol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}-3H- imidazol-4-yl)-propionic acid methyl ester, 3-{4-[4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-€-yl]-benzylamino}-2,2-dimethyl- propan-1-ol; (9-Ethyl-9H-carbazol-3-yl)-(6-phenyl-thienoI3,2-d]pyrimidin-4-yl)-amine; 10 [1 -(2-Diethylamino-ethyl)-1 H-indol-5-yl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; [1-(3-Diethylamino-propyl)-1H-indol-5-yl]-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine;(2-Bromo-thieno(3,2-b]pyridin-7-yl)-(1 H-indol-5-yl)-amine; [6-(4-Aminomethyl-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine;2. A compound of claim 1 wherein said compound is a compound of formula 1wherein R11 is -(CH2),(C6-Cio aryl) or -(CH2),(5-10 membered heterocyclic), wherein t is aninteger ranging from 0 to 6, wherein said R11 groups are optionally substituted by 1 to 5 Rs groups.
- 3-Hydroxy-2-(4-[4-(1H-indol-5-yiamino)-thieno[3t2-dJpyrimidin-6-yl]-benzylamino}- 15 propionic acid methyl ester; Furan-2-yl-(4-{4-[4-( 1 H-indol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzyl}-piperazin-1 -yl)-methanone; [6-(4-Dimethylaminomethyl-phenyl)-thieno[3I2-d]pyrimidin-4-yl]-{1H-indol-5-yl)-amine; 2-({4-(4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}-methyl-amino)- 20 éthanol; (1 -{4-(4-( 1 H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl)-pynOlidin-2-yl)-methanol; 2-(2 -(4-(4-(4-( 1 H-lndol-5-yIamino)-thieno[3,2-d]pynmidin-6-y1]-benzyl}-piperazin-1 -yl)-ethoxyj-ethanol; 25 4-(4-(1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzoic acid; (3-Methyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; ( 1 H-lndol-5-yl)-(2-methyl-6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine;N-(4-Methoxy-phenyl)-N'-(2-methyl-6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-benzene-1,4- diamine; 30 N-(2-Benzyloxy-ethyl)-N'-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine; 5-(6-Phenyl-thieno(3,2-d]pyrimidin-4-ylamino)-1 H-indole-3-carbaldehyde;(3-Bromo-1H-indol-5-y!)-(6-phenyl-thieno(3,2-d]pyhmidin-4-yi>-amine; N-( 1 H-lndol-3-ylmethyl)-N'-(6-phenyl-thteno{3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine;N-(6-Bromo-thieno(3,2-d]pyrimidin-4-yl)-N,-(4-methoxy-phenyl)-benzene-1,4-diamine; 35 N-(4-Methoxy-phenyl)-N*-[6-(2-nitro-phenyl)-thieno{3,2-dlpyrimidin-4-yll-benzene-1,4- diamine; N-(4-Methoxy-phenyl)-N‘-[6-(4-methoxy-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-benzene-1,4-diamine; N-(4-Methoxy-phenyl)-N’-(6-thiophen-2-yl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4- 40 diamine; -75- Π Ί ή 2 7 aυ ι ιό/Ο 5 N-(4-Methoxy-phenyl)-N'-Î6-{6-methoxy-pyridin-3-yl)-thieno[3,2-d]pyrimidin-4-yl]- benzene-1,4-diamine; (1H-lndol-5-yl)-[6-(4-thiomorpholin-4-ylmethyl-phenyl)-thieno[3,2-d]pyrimidin-4-yl]- amine; 6-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-benzothiazole-2-thioi; 10 N-(4-Methoxy-phenyl)-N’-thieno[3,2-d]pyrimidin-4-yl-benzene-1,4-diamine; N-(2-Methoxy-phenyl)-N’-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine,N-(6-Phenyl-thieno(3,2-d]pyrimidin-4-yl)-N'-o-tolyl-benzene-1,4-diamine;N-(6-Phenyl-thieno(3,2-d]pyrimidin-4-yl)-N'-p-tolyl-benzene-1,4-diamine;N-(3.4-Dimethoxy-phenyl)-N'-{6-phenyl-thienol3,2-d]pyrimidin-4-yl)-benzene-1,4- 15 diamine; N-(6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-N‘-(3,4,5-trimethoxy-phenyl)-benzene-1,4-diamine; N-{6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-N'-m-tolyl-benzene-1,4-diamine;N-(4-Chloro-phenyl)-N‘-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine; 20 (1H-lndol-5-yl)-[6-(6-methoxy-pyridin-3-yl)-thienoI3,2-d]pyrimidin-4-yl]-amine; N-(4-dimethylamino-phenyl)-N'-{6-phenyl-thienol3,2-d]pyrimidin-4-yl)-benzené-1,4- diamine; N-(3-Methoxy-phenyt)-N'-(6-phenyl-thieno{3,2-d]pyrimidin-4-yJ)-benzene-1,4-diamine; ( 1,3-Dibromo-1 H-indol-5-yl}-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 25 (6-Chloro-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yi)-amine; |5-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-1H-indoi-3-yl]-methanol; (6-Phenyl-thieno{3,2-d]pyrimidin-4-yl)-{3-[(3-pyrazol-1-yl-propylamino)-methyl]-1H-indol- 5-yl}-amine; U5-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-1H-indol-3-ylmethyl]-amino}-acetic acid 30 methyl ester, 2-{[5-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-1H-indol-3-ylmethyI]-amino}-ethanol;5-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-1H-indole-3-carbaldehyde oxime;(3-Methyliminomethyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;[3-{2-Nitro-vinyl)-1H-indol-5-yl]-<6-phenyl-thieno[3,2-d]pyrimidin-4-yi)-amine; 35 4-{4-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenylamino]-phenol;3. A compound of claim 2 wherein R11 is phenyl or pyridyl, wherein said phenyl andpyridyl are optionally substituted by 1 to 5 R5 groups.
- 4-Methyl-N-[4-(6-phenyl-thieno(3,2-d]pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide;N-Phenyl-N'-(6-phenyl-thieno{3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine; 35 (6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-(2H-pyrazol-3-yl)-amine; ( 1 H-Indazol-6-yl)-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine;N,N-Dimethyl-N'-(6-phenyl-thieno{3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine;(2,3-Dimethyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;N-Ethyl-N'-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine; 40 [4-(1H-lndol-5-ytamino)-thieno[3,2-d]pyrimidin-6-yl]-phenyl-methanone; ( 1 H-lndol-5-yl)-(6-p-tolyl-thieno[3,2-d]pynmidin-4-yt)-amine; -70- 011376 5 (5-Furan-2-yl-2H-pyrazol-3-yl)-thieno[3,2-d]pyrimidin-4-yl-amine; Thieno[3,2-d]pyrimidin-4-yl-(5-thiophen-2-yl-2H-pyrazol-3-yl)-amine; (5-(4-Chloro-phenyl)-2H-pyrazol-3-yl]-thienoI3,2-d]pyrimidin-4-yl-amine; (2H-Pyrazol-3-yl)-thieno(312-d]pyrimidin-4-yl-amine; Thieno[3,2-d]pyrimidin-4-yl-(5-p-tolyl-2H-pyrazol-3-y1)-amine; 10 4-(4-(1 H-Indol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl}-benzaldehyde; (6-(4-Chloro-phenyl)-thieno(3t2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; [6-(4-Fluoro-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; (1H-lndol-5-yl)-(6-thiophen-3-yl-thieno(3,2-d]pyrimidin-4-yl)-amine; 2-(3-(4-Chloro-phenyl)-5-(thieno(3,2-d]pyrimidin-4-ylamino)-pyrazol-1-yl]-ethanol; 15 (1 H-lndol-5-yl)-[6-(4-trifluoromethyl-phenyl)-thieno[3,2-d]pynmidin-4-yl]-amine; (1H-lndol-5-yl)-(6-(4-methylsulfanyl-phenyl)-thieno[3,2-d]pyrimidin-4-yl}-arnine; (1H-lndol-5-yl)-(6-(3-nitro-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-amine; (6-(3-Chloro-4-fluoro-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; [5-(4-Methoxy-phenyl)-2H-pyrazol-3-yll-thieno[3,2-d]pyrimidin-4-yl-amine; 20 4-[5-(Thieno[3,2-d]pyrimidin-4-ylamino)-1 H-pyrazol-3-yl]-benzoic acid methyl ester, (5-Methyl-2H-pyrazol-3-yl)-thieno(3,2-d]pyrimidin-4-yl-amine; 5-(6-Phenyl-thieno(3,2-d]pyrimidin-4-ylamino)-1 H-indole-2-carboxylic acid ethyl ester;(6-Benzofuran-2-yl-thieno[3,2-d]pyrimidin-4-yl)-( 1 H-indol-5-yl)-amine;Thieno[3,2-d]pyrimidin-4-yl-(5-m-tolyl-2H-pyrazol-3-yl)-amine; 25 (5-(3-Chloro-phenyl)-2H-pyrazol-3-yl]-thieno[3,2-d]pyrimidin-4-yl-amine; [6-(4-Ethyl-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; 4-(4-( 1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzoic acid methyl ester;4-[5-(Thieno[3,2-d]pyrimidin-4-ylamino)-1 H-pyrazol-3-ylJ-benzoic acid; ( 1 H-lndol-5-yl)-(6-thiophen-2-yl-thieno[3,2-d]pyrimidin-4-yl)-amine; 30 (5-(2-Chloro-phenyl)-2H-pyrazol-3-yl]-thieno[3,2-d]pyrimidin-4-yl-amine; (1H-lndol-5-yl)-(6-pyridin-3-yl-thieno[3,2-d]pyrimidin-4-yl)-amine;(1H-lndol-5-yl)-{6-(3-methoxy-phenyl)-thieno[3,2-d]pyrirnidin-4-yl]-amine; {4-(4-(1 H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl}-phenyl}-methanol; (6-(3,4-Dimethoxy-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; 35 [6-(4-Dimethylamino-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; (4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-phenyi-methanol; 4-(1 H-lndol-5-ylamino)-thieno[3,2-d]pyrimidine-6-carboxylic acid (2-dimethylaminoethyl)-amide; ( 1 H-l ndol-5-yl)-[6-(4-trifluoromethoxy-phenyl)-thieno(3,2-dlpyrimidin-4-yl]-amine; 40 ( 1 H-lndol-5-yl)-(6-(2-methoxy-phenyi)-thieno(312-d]pyrimidin-4-yl}-amine; 4-(4-( 1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-y0-phenol; -71- 011376 5 [6-(5-Diethoxymethyl-thiophen-2-yl)-thieno(3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; 4-(1 H-lndol-5-ylamino)-thieno[3,2-d)pyrimidine-6-carboxylic acid (2-methoxy-ethyl)- amide; N-{4-[4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}-N',N'-dimethyl-ethane- 1,2-diamine; 10 (1H-lndol-5-yl)-(6-{4-[(2-methoxy-ethylamino)-methyl]-phenyl}-thieno(3,2-d]pyrimidin-4- yl)-amine; (1H-lndol-5-yl)-{6-[2-(4-methyl-piperazin-1-yl)-phenyl]-thieno[3,2-d]pyrimidin-4-yl}- amine; 4- (1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidine-6-carboxyiic acid propylamide; 15 2-(4-(4-( 1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyiamino}-ethanol; [6-(2,4-Dimethoxy-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; [6-(4-Diethylamino-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; [6-(4-Ethoxy-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-(1H-indoI'5-yl)-amine; 3-(4-(4-( 1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzytamino}-propane-1,2-dioi; 20 (1H-lndol-5-yl)-(6-(4-propyiaminomethyl-phenyl)-thieno(3l2-d]pyrimidin-4-yl]-amine; (1H-lndol-5-yl)-(6-(4-((3-methoxy-propylamino)-methyl]-phenyl}-thieno{3,2-d]pyrimidin-4- yl)-amine; (6-(3-Fluoro-4-methoxy-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yi)-amine; (1H-lndol-5-yl)-(6-(3-methylsulfanyl-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-amine; 25 (1 H-lndol-5-yl)-[6-(5-methyl-thiophen-2-yl)-thieno[3,2-d]pyrimidin-4-yl]-amine; (1H-lndol-5-yl)-(6-{4-[(2-piperazin-1-yl-ethylamino)-methyl]-phenyl}-thieno[3,2- d]pyrimidin-4-yl)-amine; (6-Benzo(1,3Jdioxol-5-yl-thieno[3,2-d]pyrimidin-4-yl)-(1H-indol-5-yl)-amine; {6-(4-(1-Ethoxy-ethoxy)-phenyl]-thieno(3,2-d]pyrimidin-4-yl}-(1H-indol-5-yl)-amine; 30 (1 H-lndol-5-yl)-(6-(4-(2-pyrrolidin-1 -yl-ethoxy)-phenyl]-thieno(3,2-d]pyrimidin-4-yl}-amine; (1H-lndol-5-yl)-(6-{4-(2-methoxy-ethoxy)-phenyl]-thieno[3,2-d]pyrimidin-4-yl}-amine; (1H-lndol-5-yl)-{6-{4-((2-morpholin-4-yl-ethylamino)-methyt]-phenyl}-thieno(3,2- d]pyrimidin-4-yl)-amine; {6-[4-(2-Dimethylamino-ethoxy)-phenyl]-thieno[3,2-d]pyrimidin~4-yl}-(1H-indol-5-yl)- 35 amine; (1H-lndol-5-yl)-[6-(4-methylaminomethyl-phenyl)-ttiieno[3,2-d]pyrimidin-4-yl]-amine, 5- (6-Phenyl-thieno[3,2-d]pyrimidin~4-ylamino)-1,3-dihydro-indol-2-one;(1H-Benzotriazol-5-yl)-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine;(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylH4-(2H-tetrazol-5-yl}-phenyl]-amine; 40 N-{4-(4-{1 H-lndol-S-ytamino^thienofS^-dlpyrimidin-e-yll-benzylj-N'-methyl-ethane-l ,2- diamine; -72- 011376 5 (1 -Benzenesulfonyl-1 H-indol-5-yl)-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine; 3-{4-[4-(1H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-propan-1-ol; ( 1 H-l ndol-5-yl)-{6-[4-(4-methyl-piperazin-1 -ylmethyl)-phenyl]-thieno(3,2-d]pyrimidin-4-yl}- amine; 2-{4-{4-{ 1 H-lndol-5-ylamino)-thieno[3,2-dJpyrimidin-6-yl]-benzylamino}-propane-1,3-diol; 10 2-((2-Hydroxy-ethyl)-{4-[4-(1 H-indol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}- amino)-ethanol; {5-(4-(1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-thiophen-2-yl}-methanol; 2-(2-{4-{4-(1H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-ethoxy)- ethanol; 15 2-(2-{4-[4-(1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-ylJ-benzylamino}-ethylamino)- éthanol; [6-(4-{[2-( 1 H-lmidazol-4-yl)-ethylamino]-methyl}-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-( 1H-indol-5-yl)-amine; (1H-lndol-5-yl)-{6-{4-{2-morpholin-4-yl-ethoxy)-phenyl]-thieno[3,2-d]pyrimidin-4-yl}- 20 amine; 2- {4-(4-{1H-lndol-5-ylamino)-thieno[3l2-d]pyrimidin-6-yl]-phenoxy}-ethanol;[4-(2-Ethyl-oxazol-5-yl)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;N-(2-Methoxy-phenyl)-N'-(6-pheny1-thieno[3,2-d]pyrimidin-4-y1)-benzene-1,4-diamine;N-(4-Methoxy-phenyl)-N,-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine; 25 5-(4-(1 H-lndol-5-ylamino)-thieno{3,2-d]pyrimidin-6-yl]-thiophene-2-carbaldehyde; [5-(6-Phenyl-thieno{3,2-d]pyrimidin-4-ylamino)-1H-indol-2-yl]-methanol;(2-PhenyHH-indol-3-yl)-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine;(9H-Carbazol-3-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;(2-Methyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 30 (1 -Phenyl-ethyl)-(6-phenyl-thieno{3,2-d]pyrimidin-4-yl)-amine; (1H-lndol-5-yl)-(6-(4-{[(thiophen-2-ylmethyl)-amino]-methyI}-phenyl)-thieno(3,2- d]pyrimidin-4-yl]-amine; 3- {4-(4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-€-ylJ-benzylamino}-propionic acid methyl ester; 35 [6-(4-{[(Furan-2-ylmethyl)-amino]-methyl}-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol- 5-yl)-amine; 1-{3-{4-{4-(1H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-propyl)- pyrrolidin-2-one; N-^-^IH-Indol-S-ylaminoJ-thienoIS^-dlpyrimidin-e-ylJ-benzylJ-N'.N'-dimethyl- 40 propane-1,3-diamine; ( 1 H-lndoi-5-yl)-{6-(4-morpholin-4-ylmethyl-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-amine; -73- 011376 5 (2-(4-(4-(1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-acetylamino)- acetic acid ethyl ester; 1 .(4-(4.(4-( 1 h-I ndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzyl}-piperazin-1 -yl)-ethanone; (6-(4-((2,2-Diphenyl-ethylamino)-methyl]-phenyl}-thieno(3,2-d]pyrimidin-4-yl)-(1H-indol-10 5-yl)-amine; (1H-lndol-5-yl)-{6-[4-(2-methoxymethyl-pyrrolidin-1-ylmethyl)-phenyl]-thieno[3,2- d]pyrimidin-4-yi)-amine; N-(2-(4-(4-(1H-lndol-5-yiamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-ethyl)- acetamide; 15 [6-(4-Cyclopropylaminomethyl-phenyl)-thieno(3,2-dlpynmidin-4-yl]-(1 H-indol-5-yl)- amine; 2-{4-[4-(1H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-butan-1-ol;2-((5-(4-(1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-th>ophen-2-ylmethyl}-amino)- éthanol; 20 (1H-lndol-5-yl)-(6-{4-((2-pyrrolidin-1-yl-ethylamino)-methyl]-ph?nyl}-thieno(3,2- d]pyrimidin-4-yl)-amine; (6-(4-(Benzylamino-methyl)-phenyl]-thieno(3,2-d]pyrimidin-4-yl}-(1H-indol-5-yl)-amine; 1-{4-(4-(1H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzyl}-piperidine-4-carboxylic acid amide; 25 (1H-lndol-5-yl)-{6-[4-(pyrrolidin-3-ylaminomethyl)-phenyl]-thieno(3,2-d]pyrimidin-4-yl}- amine; (6-(4-((3-lmidazoH -yl-propylamino)-methyl]-phenyl}-thienoI3,2-d]pyrimidin-4-yl)-( 1H-indol-5-yl)-amine; N-{4-{4-( 1 H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}-N', N’-dimethyl-hexane-30 ,1,6-diamine; (1-Allyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; ( 1 -Methyl-1 H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;(1H-lndol-5-ylH6-(4-{4-ptienyl-piperazin-1-ylmethyl)-phenyl]-thieno[3,2-d]pyrimidin-4-yl}- amine; 35 N-ÊS-^-OH-Indol-S-ylaminoJ-thienofS^-dlpyrimidin-e-yij-thiophen-Z-ylmethylj-N'.N'- dimethyl-ethane-1,2-diamine; N-{5-[4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-thiophen-2-ylmethyl}-N‘-methyl- ethane-1.2-diamine; (1H-lndol-5-yl)-(6-(5-I(2-methoxy-ethylamino)-methyl]-thiophen-2-yl}-thieno{3,2-40 d]pyrimidin-4-yl)-amine; -74- 0112764. A compound of claim 1 wherein said compound is a compound of formula 1wherein X1 is CH.
- 5-Methyl-1 -[4-(6-phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenyl]-1,2-dihydro-pyrazol-3- one; (2-Methyl-benzothiazol-6-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;(S-Methylaminomethyl-IH-indoi-S-ylHe-phenyl-thienofS^-dlpyrimidin^-yO-amine;(4-Methoxy-2-methyl-phenyl)-(5-phenyl-thieno[3,2-d}pyrimidin-4-yl)-amine;[4-(4-Chloro-phenoxy)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 40 -76- 011376 5 6-(6-Phenyl-thieno[3.2-d]pyrimidin-4-ylamino)-1 H-benzo(d][1,3]oxazine-2,4-dione;5. A compound of claim 1 wherein said compound is a compound of formula 1wherein R2 is phenyl optionally substituted by 1 to 5 R5 substituents.
- 6. A compound of claim 1 wherein said compound is a compound of formula 1wherein R2 is a group of the formulaor-69- 011276 5 wherein X2 is -S- or -N(R6)-, X3 is N or CH, the dashed line in formula 3 represents an optional double bond, and the above R2 groups of formulas 3 and 5 are optionally substituted by 1to 5 R5 substituents and the R2 groups of formulas 4 and 6 are optionally substituted by 1 to 3 R5substituents.
- 7. A compound of claim 6 wherein R2 is a group of formula 3 above wherein said 10 group is optionally substituted by 1 to 5 R5 substituents.
- 8. A compound of claim 1 wherein said compound is selected from the groupconsisting of: (3-Ethynyl-phenyl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;(3-Ethynyl-phenyl)-[6-(4-methoxy-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-amine ; 15 Benzo[b]thiophen-5-yl-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; (1H-lndol-5-yl)-[6-(4-methoxy-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-amine; (1H-lndol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; (6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-(2-pyrrol-1-yl-phenyl)-amine; (5-Phenyl-1H-pyrazol-3-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 20 (5-Phenyl-1H-pyrazol-3-yl)-thieno[3,2-d]pyrimidin-4-yl-amine; ( 1 H-lndol-5-yl)-thieno[3,2-d]pyrimidin-4-yl-amine; N-(5-Phenyl)-1 -(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-1 H-[1,2,4]triazole-3,5-diamine; 3- [3-Phenyl-5-(6-phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-pyrazol-1-yl]-propionitrile·,(5-Furan-2-yl-2H-pyrazol-3-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 25 (6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-(5-thiophen-2-yl-2H-pyrazol-3-yl)-amine·, N-(6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine;N-[4-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenyl]-benzamide;N-Methyl-N'-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine;(1H-lndazol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 30 [5-(4-Chloro-phenyl)-2H-pyrazol-3-yl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; Benzothiazol-6-yl-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 4- (6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-benzamide;
- 9. A compound according to claim 1 selected from the group consisting of -77- 011376 5 (2-(4-Fluoro-phenyl)-thieno(3,2-b]pyridin-7-yl]-(1H-indol-5-yl)-amine; (1H-lndol-5-yl)-(2-thiophen-2-yl-thieno(3,2-b]pyridin-7-yl)-amine; 4-(7-( 1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzaldehyde; (1H-lndol-5-yl)-(2-(4-methylsulfanyl-phenyl)-thieno(3,2-b]pyridin-7-yl]-amine; (1H-lndol-5-yl)-thieno(3,2-b]pyridin-7-yl-amine; 10 2-(4-(7-( 1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-ylJ-phenoxy}-ethanol; (2-(4-Dimethylamino-phenyl)-thieno(3,2-b]pyridin-7-ylJ-(1H-indol-5-yl)-amine; 4-(7-( 1H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzoic acid methyl ester; (1 H-lndol-5-yl)-(2-thiophen-3-yl-thieno(3,2-b]pyridin-7-yl)-amine;(1H-lndol-5-yl)-(2-(4-((2-methoxy-ethyiamino)-methyl]-phenyl}-thieno(3,2-b]pyndin-7-yl)- 15 amine; Furan-2-yl-(4-(4-[7-(1H-indol-5-ylamino)-thieno(3l2-b]pyridin-2-yl]-benzyl}-piperazin-1- yl)-methanone; 4-(7-( 1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-phenol; 2-(2-(4-(7-(1 H-lndol-5-ylamino)-thieno(3,2-blpyridin-2-yl]-benzylamino}-ethoxy)-ethanol; 20 2-(4-[7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-ethanol; N-{4-[7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl(-benzyl}-N*,N'-dimethyV.hexane- 1,6-diamine; 2-({4-(7-(1H-lndol-5-ylamino)-thieno(3,2-b(pyridin-2-yl]-benzyl}-methyl-amino)-ethanol; (1H-lndol-5-yl)-(2-(4-[(2-piperazin-1-yl-ethylamino)-methyl]-phenyl}-thieno(3,2-b]pyridin- 7-yl)-amine; (2-(4-((3-lmidazol-1-yl-propylamino)-methyl]-phenyl}-thieno(3,2-b]pyridin-7-yl)-(1H-indol- 5-yl)-amine; 2-((2-Hydroxy-ethyl)-(4-{7-(1H-indol-5-ylamino)-thieno[3,2-b]pyrïdin-2-yl]-benzyl}-amino) éthanol; 30 (2-(4-Dimethylaminomethyl-phenyl)-thieno(3,2-b]pyridin-7-yl]-{ 1 H-indol-5-yl)-amine; N-(4-i7-(1H-lndol-5-ylaniino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-N,,N'-dimethyl-ethane- 1,2-diamine; (1-{4-[7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl}-benzyl}-pyiTolidin-2-yl)-methanol;2-(4-(4-(7-( 1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzyl}-piperazin-1 -yl)-ethanol; 35 ( 1 H-lndol-5-yl)-(2-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-thieno(3,2-b]pyridin-7-yl}-amine; 1 -(4-(7-( 1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzyl}-piperidine-4-carboxylic acid amide; (4-(7-(1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-phenyl}-methanol; 2-(4-(7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-butan-1-ol; 40 N-(4-(7-( 1 H-Indol-S-ylaminoJ-thienolS^-bJpyridin^-yll-benzyiy-N'-methyl-ethane-l ,2- diamine; -78- 011376 5 (1H-lndol-5-yl)-(2-(4-morpholin-4-ylmethyl-phenyl)-thieno[3,2-bJpyridin-7-yl]-amine; 3-(4-(7-( 1H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-propan-1-ol; 1- (3-(4-(7-( 1H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-propyl)-pyrrolidin-2-one; (1H-lndol-5-yl)-{2-(4-(2-methoxy-ethoxy)-phenyl]-thieno(3,2-b]pyridin-7-yl}-amine; 10 2-(2-(4-(7-(1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-ethylamino)- éthanol; 3-(4-(7-( 1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-2,2-dimethyl-propan-1-ol; 3-(4-(7-( 1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-propane-1,2-diol; 15 [2-(4-{[2-(1 H-lmidazol-4-yl)-ethylamino]-methyl}-phenyl)-thieno[3,2-b]pyridin-7-yl]-(1 H- indol-5-yl)-amine; N-(2-{4-[7-(1H-lndol-5-ylamino)-thieno[3l2-b]pyridin-2-yl]-benzylamino}-ethyl)- acetamide; 2- {4-(7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-acetamide; 20 2-(4-(7-( 1H-lndol-5-ylamino)-thieno[3,2-bJpyridin-2-yl]-benzylamino}-propane-1,3-diol; N-(4-Methoxy-phenyl)-N'-[2-(3-nitro-phenyl)-thieno[3,2-b]pyridin-7-yl]-benzene-1,4- diamine; (7-Methoxy-1 H-indol-5-yl)-(2-phenyl-thieno(3,2-b]pyridin-7-yl)-amine; (1H-lndol-5-yl)-[2-(4-methylaminonrcethyl-phenyl)-thieno(3,2-b}pyridin-7-yl]-amine; 25 N-(4-[7-(1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzyl}-ethane-1,2-diamine; {4-(7-(1 H-lndol-5-ylamino)-thieno{3,2-b]pyridin-2-yl]-benzylamino}-acetic acid methyl ester; N-^-P-OH-lndol-S-yiaminoi-thienoP^-blpyridin^-yll-benzyQ-N'.N'-dimethyl-propane- 1,3-diamine; 30 (1H-lndol-5-yl)-(2-pyridin-2-yl-thieno[3,2-b]pyridin-7-yl)-amine; (1H-lndol-5-yl)-(2-(4-[(2-morpholin-4-yl-ethylamino)-methyl]-phenyl}-thieno[3,2-b]pyridin- 7-yl)-amine; (1H-lndol-5-yl)-(2-[4-(pyrroltdin-3-ylaminomethyl)-phenyl]-thieno(3,2-b]pyridin-7-yl}- amine; 35 1 -(4-(4-(7-( 1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyt}-piperazin-1-yl)- ethanone; 1-(4-(7-(1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-pyrrolidine-2-carboxylicacid amide; N-(4-Methoxy-phenyl)-N'-(2-(6-methoxy-pyridin-3-yl)-thieno{3,2-b]pyridin-7-yl]-benzene-40 1,4-diamine; (1H-lndol-5-yl)-(2-pyridin-3-yi-thieno(3,2-b]pyridin-7-yl)-amine; -79- 5 4-{7-(1H-!ndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl}-but-3-yn-1-ol; N-(4-Methoxy-phenyl)-N'-(2-thiophen-2-yl-thieno[3,2-b]pyridin-7-yl)-benzene-1,4- diamine; N-(2-Hydroxy-ethyl)-4-(7-(1H-indol-5-ylamino)-thteno[3,2-b]pyridin-2-yl]-benzamide; N-(3-lmidazol-1-yl-propyl)-4-[7-(1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]- 10 benzamide; 3-{4-(4-{4-[7-(1H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-butyl)- piperazin-1-yl]-propan-1-ol; ( 1 K-lndol-5-yl)-[2-(4-{[4-(4-meîhyl-piperazin-1 -yl)-butylamino]-methyl}-phenyl)-thieno[3.2-b]pyridin-7-yl]-amine; 15 2-[4-(4-{4-[7-(1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl}-benzylamino}-butyl)- piperazin-1 -yf]-ethanol; 1- lmidazol-1-yt-3-{4-r7-(1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yi]-benzylamino}-propan-2-ol; 5-{4-[7-( 1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-pentan-1 -ol; 20 2-[2-{4-{4-[7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-piperazin-1-yl)- ethoxy]-ethanol·, (1H-lndo!-5-yl)-(2-{4-[(2-methylsijlfanyl-ethylamino)-methyl]-phenyl}-thieno[3,2-blpyridin 7-yl)-amine; 2- [(2-Hydroxy-ethyl)-(3-{4-{7-{1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-25 benzylamino}-propyl)-amino]-ethanol; N-(2-Amino-ethyl)-N'-{4-[7-(1H-indol-5-ylamino)-thieno[3,2-blpyridin-2-yl]-benzyl}- ethane-1.2-diamine; 2-(3-{4-[7-{1H-lndol-5-ylamino)-thieno(3.2-b]pyridin-2-yl]-benzylamino}-propylamino)- éthanol; 30 . N-{4-[7-(1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-hexane-1,6-diaminé; (2-Methyl-1H-indol-5-yl)-I2-{4-morpholin-4-ylmethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]- amine; 2-{4-[7-(2-Methyl-1 H-indol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-ethanol;(1H-lndol-5-yl)-[2-(6-methoxy-pyridin-3-yl)-thieno[3,2-b]pyridin-7-yl]-amine; 35 {5-[7-{ 1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-pyridin-2-yl}-methanor, N,N-Dimethyl-N’-{4-[7-(2-methyl-1H-indol-5-ylamino)-thieno[3.2-b]pyridin-2-yl]-benzyl}- propane-1,3-diamine; 2-{(2-Hydroxy-ethyl)-(3-{4-(7-(2-methyl-1H-indol-5-ylamino>-thieno[3>2-b]pyridin-2-yl]- benzylamino}-propyl)-amino}-ethanol; 40 2-{4-[7-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-propane- 1.3-diol; -80- 5 3-{4-{7-(2-Methyl-1H-indol-5-ylamino)-thienol3,2-b]pyridin-2-yl]-benzyIamino}-propane- 1,2-diol; 1- (3-{4-[7-(2-Methyl-1H-indol-5-ylamino)-thieno(3l2-blpyridin-2-yl]-benzylamino}-propyl)-pyrrolidin-2-one; N-(2-Amino-ethyl)-N,-{4-p-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-10 benzyl}-ethane-1,2-diamine; 2- (2-{4-[7-(2-Methyl-1H-indol-5-ylamino}-thieno[3,2-b]pyridin-2-yf]-benzyfamino}-ethylamino)-ethanol; 3- {4-[7-(2-MethyH H-indol-5-ylamino)-thieno(3,2-blpyridin-2-yl]-benzylamino}-propan-1 -ol; 15 1-{4-[7-(2-MethyH H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-piperidine-4- carboxylic acid amide; 2-(244-[7-{2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}- ethoxy)-ethanol; 2- (Methyl-{4-[7-(2-methyl-1H-indol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzyl}-amino)- 20 éthanol; N-Methyl-N’-{4-[7-(2-methyl-1 H-indol-5-ylamino)-thieno{3,2-b]pyridin-2-yl]-benzyl}-ethane-1,2-diamine; (1H-lndol-5-yl)-[2-(3-nitro-phenyl)-thieno[3,2-b]pyridin-7-yl]-amine; N-{4-[7-{2-MethyH H-indol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzyl}-ethane-1,2- 25 diamine; (2-Methyl-1H-indol-5-yl)-(2-{4-{(2-piperazin-1-yl-ethylamino)-methyl]-phenyl}-thieno(3l2- b]pyridin-7-yl)-amine; N,N-Dimethyl-N'-{4-[7-(2-methyl-1H-indol-5-ylamino}-thieno{3,2-b]pyridin-2-yl]-benzyl}-ethane-1,2-diamine; 30 2-{4-{7-{2-Methyl-1 H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl}-benzylamino}-butan-1-ol·, (2-Methyl-1H-indol-5-yl)-(2-{4-l(2-morpholin-4-yl-ethylamino)-methy0-phenyl}-thieno[3,2- b]pyridin-7-yl)-amine; (2-MethyHH-indol-5-ylH2-[4-(pyTOlidin-3-ylaminomethyl)-phenyl]-thieno(3.2-b]pyridin- 7-yl}-amine; 35 {6-(7-( 1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-pyridin-3-yl}-methanol; {6-P-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-pyridin-3-yl}-methanol; 3- [4-(4-{4-(7-(2-Methyl-1H-indol-5-ylamino)-thieno(3,2-b]pyridin-2-yl}-benzylamino}-butyl)-piperazin-1 -yl]-propan-1 -ol; 2-[4-(4-{4-{7-(2-Methyl-1H-indol-5-ylamino}-thiena[3,2-b]pyridin-2-yf}-benzylamino}-40 butyl)-piperazin-1 -yi]-ethanol; -81- οι un 5 (2-{4-[(3-lmidazol-1-yl-propylamino)-methyl]-phenyl}-thieno[3.2-b]pyridin-7-yl)-(2-methyl 1 H-indol-5-yl)-amine; 1- lmidazol-1-yl-3-{4-(7-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-ylJ-benzylamino}-propan-2-ol; 2- [(2-Hydroxy-ethyl)-(4-{4-[7-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b}pyridin-2-yl]- 1Q benzylamino}-butyl)-amino}-ethanot; N,N-Diethyl-N‘-{4-[7-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-propane-1,3-diamine; (2-(3-Amino-phenyl)-thieno[3>2-blpyridin-7-yl]-(1H-indol-5-yl)-amine; (2-Methyl-1H-indol-5-yl)-(2-{4-[(3-morphorm-4-yi-propylamino)-methyl]-phenyl}- 15 thieno[3,2-b]pyridin-7-yl)-amine; [2-(4-Dimethylaminomethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]-(2-methyHH-indol-5-yl)- amine; 1- {5-(2-Pyridin-2-yl-thieno[3,2-b]pyridin-7-ylamino}-2,3-dihydro-indol-1-yl]-ethanone;(2,3-Dihydro*1H-indol-5-yl)-(2-pyridin-2-yl-thieno[3,2-b]pyridin-7-yl)-amine; 20 (1 H-Benzotriazol-5-yl)-(2-pyridin-2-yl-thieno[3,2-b]pyridin-7-yl)-amine; 5-(2-Phenyl-thieno[3.2-b]pyridin-7-ylamino)-1K-indole-3-carbaldehyde; (1K-lndazol-5-yl)-(2-pyridin-2-yl-thieno[3,2-b]pyridin-7-yl)-amine; (2-Methyl-1H-indol-5-yl)-(2-pyridin-2-yl-thieno(3,2-b]pyridin-7-yl)-amine; (1H-Benzoimidazol-5-yl)-(2-phenyl-thieno[3,2-b]pyridin-7-yl)-amine; 25 5-(2-Pyridin-2-yl-thieno[3,2-b]pyridin-7-ylamino)-1 H-indole-2-carboxylic acid dimethylamide; {5-[7-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-pyridin-2-yl}-methanol; N-(3«lmidazol-1-yl-propyl)-6-[7-(1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]- nicotinamide; 30 N-(3-Hydroxy-propyl)-6-[7-(2-methyl-1H-indol-5-ytamino)-thieno[3,2-b]pyridin-2-yl]- nicotinamide; (2-(5-Amino-pyridin-2-yl)-thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)-amine; N-[2-{2-Hydroxy-ethoxy)-ethyl]-6-[7-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin- 2-yl]-nicotinamide; 35 [2-(3-Methyl·3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl]-{2-methyl-1H-indol-5-yl)-amine; 2- {1 -Methyl-5-f7-(2-methyH H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-1 H-imidazol-2-yl}-propan-2-ol; [2-( 1 -Methyl-1 H-imidazol-2-yl)-thieno(3,2-blpyridin-7-yl]-(2-methyl-1 H-indol-5-yl)-amine;(2-Methyl-1H-indol-5-yl)-(2-thiazol-2-yl-thieno(3,2-b]pyridin-7-yl)-amine; 40 2-{2-[7-{2-Methyl-1H-indol-5-ylamino)-thier)0[3,2-b]pyridin-2-yl]-thiazol-5-yl}-propan-2-ol; 4-{7-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzaldehyde; -82- 011376 5 and the pharmaceutically acceptable salts and hydrates thereof.
- 10. A compound of the formula 25 or 26or a pharmaceutically acceptable sait or hydrate thereof, wherein:wherein X1 is N or CH; 10 Z’ is halo and Z2 is -NR1R2; or Z1 is R11 and Z2 is halo; orZ1 and Z2 are each independently halo; R1 is H, Ο,-Οβ alkyl or -C(O)(C,-C6 alkyl); R2 is C6-C10 aryl or 5-13 membered heterocyclic, wherein said R2 groups are optionally15 substituted by 1 to 5 R5 substituents, each R3 is independently selected from H, -C(O)OR9, and C^Ce alkyl wherein said alkyl isoptionally substituted by 1 to 3 Rs groups; R4is R3.-OR9. or-NR’R10; each R5 is independently selected from halo, cyano, nitro, trifluoromethoxy,20 trifluoromethyl, azido, -C(O)R8, -C(O)OR8, -OC(O)R8, -OC(O)OR8, -NR6C(O)R7, -C(O)NR6R7,-NR6R7, -OR9, -SO2NR8R7, CrC6 alkyl, -(CK2)jO(CH2)qNR8R7, -(CH2),O(CH2)qOR9, -(CH2),OR9,-SfO^CrCe alkyl). -(CH2),(C6-Cio aryl), -(CH2),(5-10 membered heterocyclic), -C(O)(CH2),(C6-C10 aryl), -(CH2),0(CH2))(C6-Cio aryl), -(CH2)tO(CH2)q(5-10 membered heterocyclic).-C(O)(CH2),(5-10 membered heterocyclic), -{CH2)jNR7(CH2)qNReR7, -(CH2)jNR7CH2C(O)NR6R7,25 -(CH2)jNR7(CH2)qNR9C(O)R8, -(CH2)jNR7(CH2),O(CH2)qOR9, -(CH2)jNR7(CH2)qS(O)j(C1-C6 alkyl),-(CH2)jNR7(CH2)tR6, -SO^CH^Ce-Cw aryl), and -SO2(CH2),(5-10 membered heterocyclic),wherein j is an integer ranging from 0 to 2, t is an integer ranging from 0 to 6, q is an integerranging from 2 to 6, the -(CH2)q- and -(CH2)r moieties of the foregoing R5 groups optionallyinclude a carbon-carbon double or triple bond where t is an integer between 2 and 6, and the30 alkyl, aryl and heterocyclic moieties of the foregoing R5 groups are optionally substituted by 1 to3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R8,-C(O)OR8, -OC(O)R8, -OC(O)OR8, -NR6C(O)R7, -C(O)NR6R7, -(CH2),NR6R7, Ο,-Ce alkyl,-(CH2)t(Ce-C,o aryl), -(CH2),(5-10 membered heterocyclic), -(CH^OiCH^OR9, and -{CH2),OR9,wherein t is an integer ranging from 0 to 6 and q is an integer ranging from 2 to 6; 011 376 -83- 5 each R6 and R7 is independently selected from H, Ci-C6 alkyl, -(CH2),(C6-C,o aryl), -(CH2),(5-1O membered heterocyclic), -(CH2),O(CH2)qOR9, and -<CH2),OR9, wherein t is aninteger ranging from 0 to 6 and q is an integer ranging from 2 to 6, and the alkyl, aryl andheterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted by 1 to 3substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C{O)Ra, 10 -C(O)OR8, -CO(O)R8, -OC(O)OR8, -NR9C(O)R10, -C(O)NR9RW, -NR9R10, C,-C6 alkyl. -(CH2),(C6-C10 aryl), -(CH2),(5-10 membered heterocyclic), -(CH2)1O(CH2)qOR9, and -(CH2),OR9,wherein t is an integer ranging from 0 to 6 and q is an integer ranging from 2 to 6, with theproviso that where R6 and R7 are both attached to the same nitrogen, then R6 and R7 are notboth bonded to the nitrogen directly through an oxygen; 15 each R8 is independently selected from H, C,-Cw alkyl, -(CH2),(C6-C10 aryl), and -(CH2),(5-10 membered heterocyclic), wherein t is an integer ranging from 0 to 6; each R9 and R10 is independently selected from H and Ci-C6 alkyl; R” is H, Ci-C6 alkyl, -C(O)NR6R9, -C(O)(C6-C10 aryl). -(CHzMCg-Cw aryl), or -(CH2),(5-10 membered heterocyclic), wherein t is an integer ranging from 0 to 6, wherein said R11 groups, 20 other than H, are optionally substituted by tert-butyl-dimethyksilanyl and 1 to 3 R5 groups; and, R’2 is H. C,-C6 alkyl, -C(O)(C,-C6 alkoxy), -S(O)j(Ci-C6 alkyl), -SO2(CH2),(C6-C10 aryl), -(CH2),(C6-C10 aryl), -{CH2),(5-10 membered heterocyclic). -{CH2),O(CH2)qOR9, or -(CH2),OR9,wherein j is an integer ranging from 0 to 2, t is an integer ranging from 0 to 6 and q is an integerranging from 2 to 6. 25
- 11. A pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal which comprises a therapeutically effective amount of a compound of daim 1 and apharmaceutically acceptable carrier.
- 12. The pharmaceutical composition of daim 11 wherein said hyperproliferativedisorder is cancer.
- 13. The pharmaceutical composition of claim 12 wherein said cancer is brain, lung, kidney, rénal, ovarian, squamous cell, bladder, gastric, pancreatic, breast, head, neck,oesophageal, gynecological, prostate, colorectal or thyroid cancer.
- 14. The pharmaceutical composition of daim 11 wherein said hyperproliferative. disorder is noncancerous.
- 15. The pharmaceutical composition of claim 14 wherein said disorder is a benign hyperplasia of the skin or prostate.
- 16. A pharmaceutical composition for the treatment of a hyperproliferative disorder ina mammal which comprises a therapeutically effective amount of a compound of daim 1 incombination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, 40 alkylating agents, anti-metabolites, intercalating antibiotics, enzymes, topoisomerase inhibitors. -84- 011376 ' 5 blologlcal response modifiera, anti-hormones, and antl-androgens, and a pharmaceutically acceptable carrier.
- 17. A pharmaceutical composition for the treatment of pancreatitis or kidneydisease irt a mammal which comprises a therapeutically effective amount of a compound ofdaim 1 and a pharmaceutically acceptable carrier. 10
- 18. A pharmaceutical composition for the blastocyte implantation in a mammal which comprises a therapeutically effective amount of a compound of claim 1 and apharmaceutically acceptable carrier.
- 19. A pharmaceutical composition for treating a disease related tovasculogenesis or angiogenesis in a mammal which comprises a therapeutically effective 15 amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- 20. The pharmaceutical composition of claim 19 wherein said disease isselected from the group consisting of tumor angiogenesis, chronlc Inflammatory diseasesuch as rheumatoid arthritis, afherosclerosis, skin diseases such as psoriasis, excema, andscleroderma, diabètes, diabetic retinopathy, retinopathy of prematurity, age-related macular 20 degeneration, hemangioma, glioma, melanoma, Kaposî's sarcoma and ovarian, breast,lung, pancreatic, prostate, colon and epidermoid cancer.
- 21. The use of a compound of claim 1 for the manufacture of a médicamentfor treatment of a hyperproliferative disorder.
- 22. The use of claim 21, wherein said hyperproliferative disorder is cancer.
- 23. The use of claim 22 wherein said cancer is brain, lung, squamous cell, rénal, kidney. ovarian, bladder, gastric. pancreatic, breast. head, neck, oesophageal.prostate, colorectal, gynecological or thyroid cancer.
- 24. The use of daim 21 wherein said hyperproliferative disorder isnoncancerous.
- 25. The use of claim 24 wherein said disorder is a benign hyperplasia of the skin or prostate.
- 26. The use of a compound of claim 1 in combination with an anti-tumor agentselected from the group consisting of mitotic inhibitors, alkylating agents, antl-metabolites,intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors. enzymes. 35 topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgensfor the manufacture of a médicament for treating a hyperproliferative disorder.
- 27. The use of a compound of claim 1 for the manufacture of a médicamentfor treating pancreatitis or kidney disease.
- 28. The use of a compound of claim 1 for the manufacture of a médicament40 for treatment of blastocyte implantation. -85- 011376 10
- 29. Xrhe use of a compound of clalm 1 for the manufacture or a médicamentfor treating a'aisease related ta vasculogenesis or angiogenesis.
- 30. The use of daim 29 wherein said disease is selected from the groupconsisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoidarthritis, atherosclerosis, skin diseases such as psoriasis, excema, and scleroderma,diabètes, diabetic retinopathy,' retinopathy of prematurity, age-relatad maculardegeneration, hemangioma, glioma, melanoma, Kaposi’s sarcoma and ovarian, breast,lung, pancreatic, prostate, "colon âpd epidermoid cancer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6509797P | 1997-11-11 | 1997-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA11376A true OA11376A (en) | 2004-01-28 |
Family
ID=22060322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200000133A OA11376A (en) | 1997-11-11 | 2000-05-05 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents. |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US6492383B1 (fr) |
| EP (1) | EP1028964A1 (fr) |
| JP (1) | JP2001522853A (fr) |
| KR (1) | KR100446363B1 (fr) |
| CN (2) | CN101328186A (fr) |
| AP (1) | AP976A (fr) |
| AR (1) | AR018517A1 (fr) |
| AU (1) | AU9454198A (fr) |
| BG (1) | BG65180B1 (fr) |
| BR (1) | BR9814018A (fr) |
| CA (1) | CA2309690A1 (fr) |
| CO (1) | CO4990956A1 (fr) |
| CZ (1) | CZ20001709A3 (fr) |
| DZ (1) | DZ2646A1 (fr) |
| EA (1) | EA005889B1 (fr) |
| GT (1) | GT199800180A (fr) |
| HN (1) | HN1998000168A (fr) |
| HR (1) | HRP20000286A2 (fr) |
| HU (1) | HUP0100287A3 (fr) |
| ID (1) | ID23978A (fr) |
| IL (1) | IL135636A0 (fr) |
| IS (1) | IS5464A (fr) |
| MA (1) | MA24694A1 (fr) |
| MY (1) | MY132073A (fr) |
| NO (1) | NO20002162L (fr) |
| NZ (1) | NZ520093A (fr) |
| OA (1) | OA11376A (fr) |
| PA (1) | PA8462401A1 (fr) |
| PE (1) | PE129099A1 (fr) |
| PL (1) | PL340589A1 (fr) |
| SK (1) | SK6652000A3 (fr) |
| TN (1) | TNSN98203A1 (fr) |
| TW (1) | TW593321B (fr) |
| UA (1) | UA72881C2 (fr) |
| UY (2) | UY25238A1 (fr) |
| WO (1) | WO1999024440A1 (fr) |
| ZA (1) | ZA9810253B (fr) |
Families Citing this family (195)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE368665T1 (de) | 1997-08-22 | 2007-08-15 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| EP1006113A1 (fr) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| GB9918057D0 (en) * | 1999-07-30 | 1999-10-06 | Univ Bristol | Therapeutic agents |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| GB0010757D0 (en) * | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
| TR200402656T4 (tr) * | 2000-06-06 | 2004-11-22 | Pfizer Products Inc. | Antikanser ajanları olarak faydalı tiyofen türevleri |
| WO2002012227A2 (fr) * | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Composes chimiques |
| US7547702B2 (en) | 2000-09-20 | 2009-06-16 | Ortho-Mcneil Pharmaceutical, Inc. | 4-amino-quinazolines |
| US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
| AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| KR20020051675A (ko) * | 2000-12-23 | 2002-06-29 | 이상남 | 4-페닐아미노티에노 [3,2-디] 피리미딘 유도체 및 이의제조방법 |
| EP2796468A2 (fr) | 2001-01-05 | 2014-10-29 | Pfizer Inc | Anticorps contre le récepteur du facteur de croissance 1 analogue à l'insuline |
| ATE330956T1 (de) * | 2001-04-13 | 2006-07-15 | Pfizer Prod Inc | Bizyklisch substituierte 4- aminopyridopyrimidinderivate |
| US6995171B2 (en) | 2001-06-21 | 2006-02-07 | Agouron Pharmaceuticals, Inc. | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents |
| US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| WO2003053446A1 (fr) * | 2001-12-19 | 2003-07-03 | Smithkline Beecham Corporation | Composes de thienopyrimidine en tant qu'inhibiteurs de la proteine tyrosine kinase |
| WO2003055890A1 (fr) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Composes derives de thienopyrimidine utilises comme inhibiteurs de la prolylpeptidase, inducteurs d'apoptose et agents de traitement anticancereux |
| CA2472619A1 (fr) | 2002-01-10 | 2003-07-24 | Bayer Corporation | Derives de pyrimidine fusionnes en tant qu'inhibiteurs de la rho-kinase |
| MXPA04007191A (es) | 2002-01-23 | 2005-03-31 | Bayer Pharmaceuticals Corp | Derivados de pirimidina como inhibidores de rho-quinasa. |
| MXPA04007196A (es) | 2002-01-23 | 2005-06-08 | Bayer Pharmaceuticals Corp | Inhibidores de rho-quinasa. |
| WO2003064428A1 (fr) * | 2002-01-29 | 2003-08-07 | H. Lundbeck A/S | Furano- et thienopyrimidines en tant qu'inhibiteurs de la neurokinase |
| WO2003070241A1 (fr) * | 2002-02-15 | 2003-08-28 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de la polymerisation de tubuline |
| US20030225273A1 (en) * | 2002-03-21 | 2003-12-04 | Michaelides Michael R. | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
| UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| DE60304718T2 (de) | 2002-08-06 | 2007-04-26 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
| TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| US7276519B2 (en) * | 2002-11-25 | 2007-10-02 | Wyeth | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| PL377713A1 (pl) | 2002-12-19 | 2006-02-06 | Pfizer Inc. | Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu |
| CA2529611C (fr) | 2002-12-20 | 2009-12-15 | Pfizer Products Inc. | Derives de pyrimidine destines au traitement de la croissance cellulaire anormale |
| GEP20084341B (en) | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
| WO2005010008A1 (fr) * | 2003-07-24 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Composes tetrahydrobenzothienopyrimidinamine a substitution utiles pour le traitement de troubles hyper-proliferatifs |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| EP1663211B1 (fr) * | 2003-08-06 | 2010-01-20 | Vertex Pharmaceuticals Incorporated | Composes d'aminotriazole utiles en tant qu'inhibiteurs des proteines kinases |
| KR101028952B1 (ko) | 2003-08-14 | 2011-04-12 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| EP1660504B1 (fr) | 2003-08-29 | 2008-10-29 | Pfizer Inc. | Thienopyridine-phenylacetamides et leurs derives utiles comme nouveaux agents anti-angiogeniques |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| US7332521B2 (en) * | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
| US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| KR100807920B1 (ko) | 2003-12-23 | 2008-02-27 | 화이자 인코포레이티드 | 신규한 퀴놀린 유도체 |
| US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| CA2553513A1 (fr) * | 2004-01-22 | 2005-08-04 | Altana Pharma Ag | N-4-(6-(hetero)aryle-pyrimidine-4-ylaminophenyle)-bezenesulfonamides en tant qu'inhibiteurs de kinase |
| BRPI0511512A (pt) * | 2004-05-27 | 2007-12-26 | Pfizer Prod Inc | derivados pirrolpirimidina úteis no tratamento do cáncer |
| GB0412467D0 (en) * | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7879853B2 (en) | 2004-06-28 | 2011-02-01 | Bayer Schering Pharma Ag | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors |
| WO2006008639A1 (fr) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r |
| ES2438017T3 (es) * | 2004-07-30 | 2014-01-15 | Methylgene Inc. | Inhibidores de la señalización del receptor del VEGF y del receptor del HGF |
| BRPI0513915A (pt) | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| EP1804803A4 (fr) * | 2004-10-28 | 2008-07-30 | Irm Llc | Composes et compositions servant de modulateurs de la voie de signalisation hedgehog |
| US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
| AU2006207712A1 (en) * | 2005-01-19 | 2006-07-27 | F. Hoffmann-La Roche Ag | 5-aminoindole derivatives |
| ATE477495T1 (de) | 2005-03-16 | 2010-08-15 | Osi Pharm Inc | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
| EP3300739A3 (fr) | 2005-03-31 | 2018-07-18 | Agensys, Inc. | Anticorps et molécules correspondantes se liant aux protéines 161p2f10b |
| KR101203328B1 (ko) | 2005-04-26 | 2012-11-20 | 화이자 인코포레이티드 | P-카드헤린 항체 |
| DK1904504T3 (da) | 2005-05-20 | 2014-06-23 | Methylgene Inc | Inhibitorer af vegf-receptor- og hgf-receptorsignalering |
| NZ564283A (en) | 2005-05-20 | 2011-07-29 | Methylgene Inc | Inhibitors of VEGF receptor and HGF receptor signaling |
| US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| EP1899353A1 (fr) * | 2005-06-22 | 2008-03-19 | DeveloGen Aktiengesellschaft | Thienopyrimidines pour compositions pharmaceutiques |
| US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| WO2007026221A2 (fr) * | 2005-09-02 | 2007-03-08 | Pfizer Inc. | Procede ameliores d'elaboration de derives d'heteroaryl amide benzocondenses de thienopyridines |
| HN2006031275A (es) | 2005-09-07 | 2010-10-29 | Amgen Fremont Inc | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina |
| EP1926996B1 (fr) | 2005-09-20 | 2011-11-09 | OSI Pharmaceuticals, Inc. | Marqueurs biologiques prédictifs d'une réaction anticancéreuse aux inhibiteurs kinase du récepteur du facteur de croissance 1 analogue à l'insuline |
| PE20070619A1 (es) * | 2005-09-27 | 2007-07-02 | Wyeth Corp | TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA |
| US20070099877A1 (en) * | 2005-11-02 | 2007-05-03 | Cytovia, Inc. | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US20070099941A1 (en) * | 2005-11-02 | 2007-05-03 | Cytovia, Inc. | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2007056214A2 (fr) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc | N-alkyl-n-aryl-thienopyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose et utilisation associee |
| KR101086967B1 (ko) | 2005-11-15 | 2011-11-29 | 어레이 바이오파마 인크. | 과다증식성 질환의 치료를 위한 erbb 유형 i 수용체티로신 키나제 억제제로서의 n4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물 |
| EP1989211A2 (fr) * | 2006-01-30 | 2008-11-12 | Array Biopharma, Inc. | Composés hétérobicycliques de thiophène et leurs méthodes d'utilisation |
| WO2007107005A1 (fr) * | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibiteurs de l'activité protéine tyrosine kinase |
| CN101437519A (zh) * | 2006-03-31 | 2009-05-20 | 艾博特公司 | 吲唑化合物 |
| CN101466716A (zh) * | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶 |
| EA200802058A1 (ru) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
| EP1889847A1 (fr) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Dérivés de pyrrolopyrimidine pour applications pharmaceutiques |
| WO2008058126A2 (fr) | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Dérivés d'imidazo[1,2-b]pyridazine et de pyrazolo[1,5-a]pyrimidine et utilisation de ceux-ci comme inhibiteurs de protéines kinases |
| PE20081679A1 (es) | 2006-12-07 | 2008-12-18 | Hoffmann La Roche | Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso |
| JP2010514810A (ja) * | 2006-12-29 | 2010-05-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Axlインヒビターとして有用な置換トリアゾール |
| WO2008082839A2 (fr) * | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Inhibiteurs de la pim kinase comme agents chimiothérapeutiques destinés à lutter contre le cancer |
| WO2008086053A1 (fr) * | 2007-01-03 | 2008-07-17 | Virobay, Inc. | Inhibiteurs du vhc |
| EP2158207B1 (fr) * | 2007-06-12 | 2011-05-25 | F. Hoffmann-La Roche AG | Thiazolopyrimidines et leur utilisation comme inhibiteurs de la phosphatidylinositol-3 kinase (pi3k) |
| EP2014662A1 (fr) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Indolylalkylthienopyrimidylamine en tant que modulateurs du récepteur EP2 |
| EP2014663A1 (fr) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine en tant que modulateurs du récepteur EP2 |
| JP5736171B2 (ja) | 2007-09-24 | 2015-06-17 | ジェネンテック, インコーポレイテッド | チアゾロピリミジンpi3k阻害剤化合物および使用方法 |
| KR20100095528A (ko) * | 2007-10-18 | 2010-08-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 디하이드로티에노[3,2-d]피리미딘의 제조방법 및 상기 제조방법에서 사용된 중간체 |
| EP2214675B1 (fr) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Procédé de préparation de composés de thiénopyrimidine |
| US7956068B2 (en) * | 2007-11-15 | 2011-06-07 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| MX2010005671A (es) * | 2007-11-28 | 2010-06-25 | Dana Farber Cancer Inst Inc | Inhibidores de miristato de moleculas pequeñas contra bcr-abl y metodos de uso. |
| EP2229388A4 (fr) * | 2008-01-11 | 2012-03-07 | Glenmark Pharmaceuticals Sa | Dérivés de pyrimidine condensée en tant que modulateurs de trpv3 |
| EA201001262A1 (ru) | 2008-02-07 | 2011-04-29 | Вайробей, Инк. | Ингибиторы катепсина в |
| NZ588355A (en) | 2008-03-05 | 2012-03-30 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity |
| US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| AU2009286734A1 (en) | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| WO2010045495A2 (fr) | 2008-10-16 | 2010-04-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anticorps entièrement humains dirigés contre un antigène associé au mélanome de masse moléculaire élevée et leurs utilisations |
| KR101126736B1 (ko) * | 2008-11-27 | 2012-04-12 | 주식회사 레고켐 바이오사이언스 | 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물 |
| CA2748943A1 (fr) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Inhibiteurs pyrrolopyrimidinyle de l'axi kinase |
| EP2400985A2 (fr) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Thérapie anti-cancer combinée |
| JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法 |
| WO2010098866A1 (fr) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| EP2401614A1 (fr) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation |
| WO2010099138A2 (fr) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation |
| BRPI1006189A2 (pt) | 2009-03-12 | 2020-08-18 | Genentech Inc | uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer |
| WO2010136491A1 (fr) * | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Composés bicycliques indole-pyrimidine inhibiteurs de pi3k sélectifs pour p110 delta et leurs procédés d'utilisation |
| US8173650B2 (en) | 2009-05-27 | 2012-05-08 | Genentech, Inc. | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
| BR112012000735A2 (pt) | 2009-07-13 | 2016-11-16 | Genentech Inc | "métodos, kits e conjuntos de compostos" |
| US20120128670A1 (en) | 2009-07-31 | 2012-05-24 | OSI Pharmaceuticals, LLC | mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY |
| JP2013503846A (ja) | 2009-09-01 | 2013-02-04 | ファイザー・インク | ベンズイミダゾール誘導体 |
| CN102597776A (zh) | 2009-09-11 | 2012-07-18 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌剂的可能性升高的患者的方法 |
| JP5606537B2 (ja) | 2009-09-17 | 2014-10-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 癌患者における診断使用のための方法及び組成物 |
| WO2011073521A1 (fr) | 2009-12-15 | 2011-06-23 | Petri Salven | Méthodes pour l'enrichissement de cellules progénitrices endothéliales adultes et leurs utilisations |
| RS55487B2 (sr) | 2010-02-12 | 2024-06-28 | Pfizer | Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona |
| PH12012501693A1 (en) | 2010-02-26 | 2012-11-05 | Boehringer Ingelheim Int | 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions |
| UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| BR112012021453A2 (pt) | 2010-02-26 | 2017-02-21 | Boehringer Ingelheim Int | tienopirimidina, sua composição farmacêutica e seu uso |
| AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP2519826A2 (fr) | 2010-03-03 | 2012-11-07 | OSI Pharmaceuticals, LLC | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1 |
| CN103038643A (zh) | 2010-04-16 | 2013-04-10 | 基因泰克公司 | 作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a |
| CN102250112A (zh) * | 2010-05-18 | 2011-11-23 | 上海再启生物技术有限公司 | 7-溴-4-氨基噻吩并嘧啶的制备方法 |
| WO2011149126A1 (fr) * | 2010-05-26 | 2011-12-01 | 한국과학기술연구원 | Composition pharmaceutique comprenant un composé anti-inflammatoire présentant une fonction d'inhibition de la tyrosine kinase |
| CN102971327B (zh) * | 2010-05-26 | 2016-04-20 | 韩国科学技术研究院 | 具有多种酪氨酸激酶抑制活性的抗炎化合物以及含有这些化合物的药物组成物 |
| WO2011153224A2 (fr) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Procédés diagnostiques et compositions de traitement du cancer |
| JP2013538042A (ja) | 2010-06-16 | 2013-10-10 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | エンドプラスミンに対する抗体およびその使用 |
| US20130225581A1 (en) | 2010-07-16 | 2013-08-29 | Kyowa Hakko Kirin Co., Ltd | Nitrogen-containing aromatic heterocyclic derivative |
| BR112013001433A2 (pt) | 2010-07-19 | 2016-05-31 | Hoffmann La Roche | método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer |
| CN103109189A (zh) | 2010-07-19 | 2013-05-15 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌疗法的可能性升高的患者的方法 |
| WO2012012750A1 (fr) | 2010-07-23 | 2012-01-26 | Trustees Of Boston University | Inhibiteurs anti-despr comme agents thérapeutiques pour l'inhibition de l'angiogenèse pathologique et de l'invasivité des cellules tumorales et pour l'imagerie moléculaire et l'administration ciblée |
| EP2616441B1 (fr) | 2010-09-17 | 2019-08-07 | Purdue Pharma L.P. | Composés de pyridine et ses utilisations |
| WO2012042421A1 (fr) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Procédé de traitement de la croissance cellulaire anormale |
| WO2012052948A1 (fr) | 2010-10-20 | 2012-04-26 | Pfizer Inc. | Dérivés de pyridine-2 en tant que modulateurs des récepteurs smoothened |
| WO2012088254A1 (fr) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Polythérapie par inducteur et inhibiteur d'autophagie pour le traitement de néoplasmes |
| WO2012106522A2 (fr) | 2011-02-04 | 2012-08-09 | Duquesne University Of The Holy Spirit | Inhibiteurs pyrimidines bicycliques et tricycliques de tyrosine kinase ayant une activité antitubuline, et méthodes de traitement d'un patient |
| WO2012116040A1 (fr) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
| EP2734530A1 (fr) | 2011-07-19 | 2014-05-28 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
| MD20140023A2 (ro) | 2011-09-22 | 2014-06-30 | Pfizer Inc. | Derivaţi de pirolpirimidină şi purină |
| AU2011378675B2 (en) | 2011-10-04 | 2017-10-05 | Epsilogen Ltd | IgE anti -HMW-MAA antibody |
| CN103087077B (zh) * | 2011-11-03 | 2016-05-18 | 上海希迈医药科技有限公司 | 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| RU2014114015A (ru) | 2011-11-08 | 2015-12-20 | Пфайзер Инк. | Способы лечения воспалительных расстройств с использованием антител против m-csf |
| MX349548B (es) | 2012-01-10 | 2017-08-02 | Hoffmann La Roche | Compuestos de tienopirimidina. |
| FR2988722B1 (fr) | 2012-04-03 | 2014-05-09 | Sanofi Sa | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
| WO2013152252A1 (fr) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Polythérapie antinéoplasique |
| CN103360407B (zh) * | 2012-04-10 | 2016-06-22 | 上海希迈医药科技有限公司 | 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN103664991B (zh) * | 2012-09-19 | 2016-12-28 | 中国科学院福建物质结构研究所 | 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途 |
| WO2014062838A2 (fr) | 2012-10-16 | 2014-04-24 | Tolero Pharmaceuticals, Inc. | Modulateurs de pkm2 et procédés pour les utiliser |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| WO2014130923A2 (fr) | 2013-02-25 | 2014-08-28 | Genentech, Inc. | Procédés et compositions pour détecter et traiter un mutant d'akt résistant aux médicaments |
| RU2693480C2 (ru) | 2013-03-14 | 2019-07-03 | Толеро Фармасьютикалз, Инк. | Ингибиторы jak2 и alk2 и способы их использования |
| US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| TW201534597A (zh) * | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
| CN105764511B (zh) | 2013-10-04 | 2019-01-11 | 艾普托斯生物科学公司 | 用于治疗癌症的组合物和方法 |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| PT3126521T (pt) | 2014-04-04 | 2019-06-27 | Crown Bioscience Inc Taicang | Gene de fusão hnf4g-rspo2 |
| WO2015155624A1 (fr) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dérivés de dihydropyrrolopyrimidine |
| WO2015166373A1 (fr) | 2014-04-30 | 2015-11-05 | Pfizer Inc. | Dérivés de dihétérocycle liés à cycloalkyle |
| WO2016001789A1 (fr) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer |
| BR112017000714A2 (pt) * | 2014-07-16 | 2018-01-09 | Novogen ltd | indols funcionalizados e substituídos como agentes anti-câncer |
| ES2848857T3 (es) | 2014-07-31 | 2021-08-12 | Us Gov Health & Human Services | Anticuerpos monoclonales humanos contra EphA4 y su uso |
| JP6621477B2 (ja) | 2014-12-18 | 2019-12-18 | ファイザー・インク | ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用 |
| BR112017022666A8 (pt) | 2015-04-20 | 2022-10-18 | Tolero Pharmaceuticals Inc | Preparando resposta à alvocidib por perfilamento mitocondrial |
| CN107709344B (zh) | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | 用于治疗黄病毒科病毒和癌症的核苷类似物 |
| CN111349118B (zh) | 2015-05-18 | 2023-08-22 | 住友制药肿瘤公司 | 具有增加的生物利用度的阿伏西地前药 |
| WO2017009751A1 (fr) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Dérivés de pyrimidine |
| RU2759963C2 (ru) | 2015-08-03 | 2021-11-19 | Сумитомо Даиниппон Фарма Онколоджи, Инк. | Комбинированные терапии для лечения рака |
| JP6877429B2 (ja) | 2015-12-03 | 2021-05-26 | アジオス ファーマシューティカルズ, インコーポレイテッド | Mtapヌル癌を処置するためのmat2a阻害剤 |
| EP3394056B1 (fr) | 2015-12-22 | 2021-04-14 | Shy Therapeutics LLC | Composés pour le traitement du cancer et de maladies inflammatoires |
| EP4001277A3 (fr) * | 2016-03-11 | 2022-09-14 | AC Immune SA | Composes bicycliques pour le diagnostic et le traitement |
| CN107652273B (zh) * | 2016-07-26 | 2020-05-01 | 沈阳药科大学 | 嘧啶类衍生物及其制备方法和应用 |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| JP6619519B2 (ja) | 2016-12-19 | 2019-12-11 | トレロ ファーマシューティカルズ, インコーポレイテッド | プロファイリングペプチドおよび感受性プロファイリングのための方法 |
| CA3066939A1 (fr) | 2017-06-21 | 2018-12-27 | SHY Therapeutics LLC | Composes interagissant avec la superfamille ras destines a etre utilises dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques |
| WO2019055579A1 (fr) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib |
| WO2019075367A1 (fr) | 2017-10-13 | 2019-04-18 | Tolero Pharmaceuticals, Inc. | Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer |
| CA3103995A1 (fr) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Procedes de traitement de maladies associees a l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destines a etre utilises dans ceux-ci |
| EP3883935A4 (fr) * | 2018-11-20 | 2022-08-10 | Georgetown University | Compositions et méthodes de traitement de troubles neurodégénératifs, myodégénératifs et du stockage lysosomal |
| MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| TW202039481A (zh) | 2018-12-21 | 2020-11-01 | 美商西建公司 | Ripk2之噻吩并吡啶抑制劑 |
| NZ778055A (en) | 2019-02-12 | 2025-11-28 | Sumitomo Pharma America Inc | Formulations comprising heterocyclic protein kinase inhibitors |
| CA3129067A1 (fr) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Composes de thioeno[3,2-b]pyridin-7-amine pour le traitement de la dysautonomie familiale |
| WO2020167624A1 (fr) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Composés de pyrrolo[2,3-d] pyrimidine pour le traitement de la dysautonomie familiale |
| WO2020168927A1 (fr) * | 2019-02-19 | 2020-08-27 | 四川科伦博泰生物医药股份有限公司 | Composé cyclique condensé contenant de l'azote, son procédé de préparation et son utilisation |
| KR20210146287A (ko) * | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
| JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
| WO2020198077A1 (fr) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant |
| WO2021057256A1 (fr) * | 2019-09-29 | 2021-04-01 | 四川科伦博泰生物医药股份有限公司 | Composé azoté hétérocyclique, composition pharmaceutique le contenant, son procédé de préparation et utilisation associée |
| WO2021118929A1 (fr) * | 2019-12-12 | 2021-06-17 | Ptc Therapeutics, Inc. | Composés pour le traitement de la dysautonomie familiale |
| WO2021155006A1 (fr) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations |
| CN115746017B (zh) * | 2022-11-30 | 2024-06-07 | 英维沃化工科技(广州)有限公司 | 一种噻吩并嘧啶类化合物及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0071227B1 (fr) * | 1981-07-31 | 1987-11-11 | Sloan-Kettering Institute For Cancer Research | Bêta-glycosyl C-nucléosides à activité anti-leucémique |
| EP0364598A4 (en) * | 1988-03-02 | 1992-01-15 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof |
| BR9101256A (pt) | 1990-03-30 | 1991-11-05 | Dowelanco | Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida |
| US5187168A (en) | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
| CA2129337A1 (fr) * | 1992-02-19 | 1993-09-02 | Jotham W. Coe | Composes heterocycliques pour ameliorer l'activite antitumorale |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| CA2223081C (fr) * | 1995-06-07 | 2001-03-06 | Pfizer Inc. | Derives de pyrimidine heterocycliques a noyaux condenses |
| AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| ES2200039T3 (es) | 1995-12-08 | 2004-03-01 | Pfizer Inc. | Derivados heterociclicos sustituidos como antagonistas de crf. |
| WO1997029110A1 (fr) | 1996-02-07 | 1997-08-14 | Janssen Pharmaceutica N.V. | Thiophenopyrimidines |
| ES2191187T3 (es) | 1996-07-13 | 2003-09-01 | Glaxo Group Ltd | Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa. |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
-
1998
- 1998-10-22 NZ NZ520093A patent/NZ520093A/en unknown
- 1998-10-22 CN CNA2008101000200A patent/CN101328186A/zh active Pending
- 1998-10-22 UA UA2000042376A patent/UA72881C2/uk unknown
- 1998-10-22 EA EA200000391A patent/EA005889B1/ru unknown
- 1998-10-22 WO PCT/IB1998/001691 patent/WO1999024440A1/fr not_active Ceased
- 1998-10-22 JP JP2000520449A patent/JP2001522853A/ja active Pending
- 1998-10-22 BR BR9814018-3A patent/BR9814018A/pt not_active Application Discontinuation
- 1998-10-22 ID IDW20000864A patent/ID23978A/id unknown
- 1998-10-22 SK SK665-2000A patent/SK6652000A3/sk unknown
- 1998-10-22 KR KR10-2000-7005010A patent/KR100446363B1/ko not_active Expired - Fee Related
- 1998-10-22 HR HR20000286A patent/HRP20000286A2/hr not_active Application Discontinuation
- 1998-10-22 AU AU94541/98A patent/AU9454198A/en not_active Abandoned
- 1998-10-22 CN CN98811858A patent/CN1280580A/zh active Pending
- 1998-10-22 PL PL98340589A patent/PL340589A1/xx not_active Application Discontinuation
- 1998-10-22 IL IL13563698A patent/IL135636A0/xx unknown
- 1998-10-22 EP EP98947716A patent/EP1028964A1/fr not_active Withdrawn
- 1998-10-22 CZ CZ20001709A patent/CZ20001709A3/cs unknown
- 1998-10-22 HU HU0100287A patent/HUP0100287A3/hu unknown
- 1998-10-22 CA CA002309690A patent/CA2309690A1/fr not_active Abandoned
- 1998-10-26 HN HN1998000168A patent/HN1998000168A/es unknown
- 1998-10-29 PA PA19988462401A patent/PA8462401A1/es unknown
- 1998-11-05 AP APAP/P/1998/001389A patent/AP976A/en active
- 1998-11-06 PE PE1998001069A patent/PE129099A1/es not_active Application Discontinuation
- 1998-11-06 TW TW087118534A patent/TW593321B/zh not_active IP Right Cessation
- 1998-11-09 AR ARP980105653A patent/AR018517A1/es not_active Application Discontinuation
- 1998-11-09 UY UY25238A patent/UY25238A1/es unknown
- 1998-11-09 GT GT199800180A patent/GT199800180A/es unknown
- 1998-11-09 MY MYPI98005088A patent/MY132073A/en unknown
- 1998-11-10 DZ DZ980256A patent/DZ2646A1/fr active
- 1998-11-10 ZA ZA9810253A patent/ZA9810253B/xx unknown
- 1998-11-10 TN TNTNSN98203A patent/TNSN98203A1/fr unknown
- 1998-11-10 MA MA25338A patent/MA24694A1/fr unknown
- 1998-11-11 CO CO98066593A patent/CO4990956A1/es unknown
-
1999
- 1999-01-11 UY UY25344A patent/UY25344A1/es not_active IP Right Cessation
-
2000
- 2000-02-10 US US09/502,129 patent/US6492383B1/en not_active Expired - Fee Related
- 2000-04-19 IS IS5464A patent/IS5464A/is unknown
- 2000-04-27 NO NO20002162A patent/NO20002162L/no not_active Application Discontinuation
- 2000-05-05 OA OA1200000133A patent/OA11376A/en unknown
- 2000-05-09 BG BG104412A patent/BG65180B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA11376A (en) | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents. | |
| KR101483215B1 (ko) | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 | |
| US6413971B1 (en) | Fused bicyclic pyrimidine derivatives | |
| US6995171B2 (en) | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | |
| JP2003535867A (ja) | 抗癌剤として有用なチオフェン誘導体 | |
| JP2013523711A (ja) | アデノシンa2a受容体拮抗薬としての4−アミノピリミジン誘導体 | |
| KR20110044053A (ko) | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물 | |
| CN103703009A (zh) | 作为二酰基甘油酰基转移酶抑制剂的新化合物 | |
| US20020004511A1 (en) | Thiophene derivatives useful as anticancer agents | |
| US20030162795A1 (en) | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | |
| JP5070058B2 (ja) | 過増殖性疾患の処置のための上皮増殖因子受容体(egfrs)のチロシンキナーゼ活性のインヒビターとしてのベンゾチエノ’2,3−d!ピリミジン化合物 | |
| AU2002301080B2 (en) | Thienopyrimidine and Thienopyridine Derivatives Useful as Anticancer Agents | |
| MXPA00004491A (en) | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |